当前位置:主页 > 医学论文 > 呼吸病论文 >

不同雾化方法吸入布地奈德对慢性阻塞性肺疾病急性加重期患者胸肺顺应性及动脉血气指标的影响

发布时间:2018-11-23 10:03
【摘要】:目的探讨不同雾化方法吸入布地奈德对慢性阻塞性肺疾病急性加重期(AECOPD)患者胸肺顺应性及动脉血气指标的影响。方法 83例慢阻肺急性加重期患者根据随机数字法分成两组,其中,40例采用空气泵驱动雾化治疗(空气泵驱动组),43例采用氧驱动雾化治疗(氧驱动组)。对慢阻肺症状评分(CAT)、血气分析指标及胸肺顺应性进行测定。结果治疗前后,空气泵驱动组及氧气驱动组雾化吸入布地奈德在CAT评分、胸肺顺应性(Ct、CI和Cth)、肺通气指标(FEV1.0、PEF、MIP和MEP)及血液酸碱度(pH)和动脉血氧分压(PaO)值2比较差异无统计学意义(P0.05),但空气泵驱动组在改善PaCO_2水平上优于氧气驱动组(P0.05)。结论孟鲁司特钠联合BiPAP呼吸机治疗哮喘-慢性阻塞性肺疾病重叠综合征有较好的临床疗效,值得推广和应用。
[Abstract]:Objective to investigate the effects of inhaled budesonide on thoracic lung compliance and arterial blood gas in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Eighty-three patients with acute exacerbation of COPD were randomly divided into two groups: 40 cases were treated with air pump driven atomization (air pump driven group) and 43 cases were treated with oxygen driven atomization therapy (oxygen driven group). The indexes of (CAT), blood gas analysis and thoracic lung compliance were measured. Results before and after treatment, budesonide inhalation in air pump driven group and oxygen driven group was used in CAT score, thoracic lung compliance (Ct,CI and Cth), pulmonary ventilation index) (FEV1.0,PEF,). MIP and MEP), (pH) of blood pH and (PaO) value of arterial partial pressure of oxygen had no significant difference (P0.05), but air pump driving group was better than oxygen driven group in improving PaCO_2 level (P0.05). Conclusion Montelukast sodium combined with BiPAP respirator has a good clinical effect in the treatment of asthmatic-chronic obstructive pulmonary disease overlap syndrome, which is worth popularizing and applying.
【作者单位】: 武警河北总队医院呼吸科;
【分类号】:R563.9

【参考文献】

相关期刊论文 前10条

1 孟庆华;李承红;王小江;石奕;冯琼;;噻托溴铵联合孟鲁思特对慢性阻塞性肺疾病患者血液流变学、肺功能及血清细胞因子水平的影响[J];海南医学院学报;2016年22期

2 丁震;刘骅;陈洁;李秀;;不同雾化方法吸入布地奈德在慢阻肺急性加重期疗效及血药浓度对比研究[J];临床肺科杂志;2015年11期

3 张春美;丁震;裴,

本文编号:2351186


资料下载
论文发表

本文链接:https://www.wllwen.com/yixuelunwen/huxijib/2351186.html


Copyright(c)文论论文网All Rights Reserved | 网站地图 |

版权申明:资料由用户b6e85***提供,本站仅收录摘要或目录,作者需要删除请E-mail邮箱bigeng88@qq.com